Klinefelter Syndrome

1. Clinical Overview

Summary

Klinefelter syndrome (KS) is the most common sex chromosome aneuploidy in males, characterized by the presence of one or more supernumerary X chromosomes (most commonly 47,XXY karyotype). With an incidence of approximately 1 in 500-660 live male births, it represents the most frequent genetic cause of primary hypogonadism and male infertility. [1,2] Despite its prevalence, only 25% of affected individuals are diagnosed during their lifetime, with many cases identified incidentally during fertility investigations in adulthood. [3]

The syndrome results from non-disjunction during parental meiosis, leading to testicular dysgenesis and progressive loss of seminiferous tubule function. The pathognomonic triad comprises hypergonadotropic hypogonadism (elevated LH/FSH with low testosterone), small firm testes (less than 4 mL bilaterally), and azoospermia. [4] Additional features include tall stature with eunuchoid proportions, gynaecomastia (affecting 38-75% of patients), reduced facial and body hair, and increased risk of metabolic, cardiovascular, and autoimmune complications. [5,6]

Contemporary management centers on testosterone replacement therapy (TRT) initiated during adolescence to optimize bone mineralization, body composition, sexual function, and neurocognitive outcomes. [7] Fertility preservation through testicular sperm extraction (TESE) combined with intracytoplasmic sperm injection (ICSI) has revolutionized reproductive options, with sperm retrieval success rates of 40-50% when performed in adolescence or early adulthood. [8,9]

Key Facts

Clinical Pearls

"The Great Imitator of Delayed Puberty": Klinefelter syndrome should be in the differential for every boy with delayed or incomplete puberty. The combination of tall stature with small testes is the key discriminator from constitutional delay.

"High Gonadotrophins, Low Testosterone": This is primary testicular failure. The pituitary responds normally by increasing LH and FSH, but the dysgenic testes cannot respond—hence hypergonadotropic hypogonadism.

"50% Maternal, 50% Paternal": Unlike many genetic conditions, the extra X chromosome arises from maternal non-disjunction in approximately 50-55% of cases and paternal in 45-50%, with advanced maternal age being a modest risk factor. [10]

"Tall with Small Testes = Red Flag": The combination of height > 75th percentile with testicular volume less than 4 mL (post-pubertal) should trigger karyotype testing. Normal prepubertal testicular volume is 1-3 mL; failure to enlarge during puberty is pathognomonic.

"Testosterone Helps Everything Except Fertility": TRT dramatically improves bone density, muscle mass, sexual function, energy, mood, and cardiovascular risk profile—but does NOT restore spermatogenesis. Fertility requires TESE-ICSI.

"Earlier is Better for Fertility": Sperm retrieval rates decline with age as testicular fibrosis progresses. TESE performed in adolescence (16-18 years) or early twenties yields higher success than delayed attempts. [9]

"Breast Cancer Risk 20-50x Baseline": Although absolute risk remains low (lifetime risk ~3% vs. 0.1% in 46,XY males), this represents the highest relative risk of any male population. Annual breast examination and patient education are essential. [11]

"Testicular Cancer Risk is REDUCED": Paradoxically, despite gonadal dysgenesis, testicular cancer risk is lower than in the general male population—in contrast to other disorders of sex development (e.g., androgen insensitivity, gonadal dysgenesis). [12]

"Mosaicism Means Milder Phenotype": Males with 46,XY/47,XXY mosaicism typically have milder features, larger testes, better androgen production, and occasionally preserved fertility with oligospermia rather than azoospermia. [13]

---

2. Epidemiology

Incidence and Prevalence

Klinefelter syndrome is the most common sex chromosome disorder, affecting approximately 1 in 500 to 1 in 660 live male births. [1,2] This incidence has remained stable across populations and ethnicities, suggesting a consistent rate of chromosomal non-disjunction during meiosis.

Diagnostic Rate and Age at Diagnosis

Despite its high incidence, Klinefelter syndrome remains profoundly underdiagnosed:

• Only 25% of affected individuals are diagnosed during their lifetime [3]
• Median age at diagnosis: 27 years (range: infancy to 70s)
• 75% remain undiagnosed and never receive appropriate treatment

The increasing use of non-invasive prenatal testing (NIPT) has led to rising prenatal detection rates, creating new counseling and management challenges. [15]

Karyotype Distribution

Higher-order aneuploidies (≥48 chromosomes) demonstrate progressively severe neurodevelopmental and physical phenotypes. [16]

Risk Factors for Non-Disjunction

Unlike trisomy 21, the risk of Klinefelter syndrome shows only a modest association with advanced maternal age:

Approximately 50-55% of cases result from maternal meiosis I errors, and 45-50% from paternal meiosis. [10]

---

3. Aetiology and Pathophysiology

Genetic Mechanism

Klinefelter syndrome arises from chromosomal non-disjunction during parental gametogenesis, resulting in gametes with an extra sex chromosome (either 24,XX ova or 24,XY sperm). Fertilization produces a 47,XXY zygote.

NORMAL MEIOSIS                    NON-DISJUNCTION
    
Parent: 46,XX                     Parent: 46,XX
    ↓ Meiosis                         ↓ Error in Meiosis I/II
Gamete: 23,X                      Gamete: 24,XX
    +                                 +
Gamete: 23,Y                      Gamete: 23,Y
    ↓                                 ↓
Zygote: 46,XY (Normal)           Zygote: 47,XXY (Klinefelter)

Parental Origin:

• Maternal (meiosis I or II): 50-55%
• Paternal (meiosis I or II): 45-50%

Mosaicism (46,XY/47,XXY) occurs when non-disjunction happens post-fertilization during early mitotic divisions, resulting in two cell lines. [13]

Molecular Pathophysiology

Gene Dosage Imbalance

Although most genes on the supernumerary X chromosome undergo X-inactivation (forming a Barr body), approximately 15% of X-linked genes escape inactivation, leading to gene dosage imbalance. [17] These genes are implicated in the syndromic features:

The SHOX gene (short stature homeobox) escapes X-inactivation and is expressed in duplicate, contributing to tall stature and long limbs. [17]

Exam Detail: Why do 47,XXY males have tall stature despite low testosterone?

This apparent paradox reflects two mechanisms:

1. SHOX gene overexpression: Duplication of this pseudoautosomal region gene promotes long bone growth
2. Delayed epiphyseal closure: Hypogonadism delays epiphyseal fusion, allowing prolonged growth
3. Eunuchoid proportions: Arm span exceeds height due to disproportionate long bone growth

Thus, tall stature results from BOTH genetic (SHOX) and hormonal (low testosterone) factors operating synergistically.

Testicular Pathology

The supernumerary X chromosome exerts a toxic effect on germ cells, leading to progressive testicular degeneration:

Fetal Period:

• Testes develop normally initially
• Germ cell numbers are normal until mid-gestation
• Progressive germ cell apoptosis begins in 2nd-3rd trimester

Childhood:

• Prepubertal testes appear histologically near-normal
• Sertoli and Leydig cells are present
• Germ cell numbers already reduced

Puberty and Adulthood:

• Accelerated germ cell loss at puberty
• Seminiferous tubule hyalinization and fibrosis
• Leydig cell hyperplasia (responding to high LH) but insufficient testosterone production
• By adulthood: testes are small (1-2 mL), firm, with extensive fibrosis

Histological Features (adult testicular biopsy):

• Seminiferous tubule sclerosis and hyalinization
• Absence of spermatogenesis (Sertoli-cell-only pattern)
• Leydig cell clusters (hyperplasia)
• Thickened basement membrane

Hormonal Pathophysiology

Klinefelter syndrome is a model of primary hypergonadotropic hypogonadism:

┌─────────────────────────────────────────────────┐
│  NORMAL MALE HPG AXIS                           │
├─────────────────────────────────────────────────┤
│                                                 │
│  Hypothalamus → GnRH                            │
│       ↓                                         │
│  Pituitary → LH + FSH                           │
│       ↓                                         │
│  Testes → Testosterone + Inhibin B              │
│       ↓                                         │
│  Negative feedback to hypothalamus/pituitary    │
│                                                 │
└─────────────────────────────────────────────────┘

┌─────────────────────────────────────────────────┐
│  KLINEFELTER SYNDROME HPG AXIS                  │
├─────────────────────────────────────────────────┤
│                                                 │
│  Hypothalamus → GnRH (NORMAL)                   │
│       ↓                                         │
│  Pituitary → ↑↑LH + ↑↑FSH (ELEVATED)            │
│       ↓                                         │
│  Dysgenic Testes → ↓Testosterone + ↓Inhibin B   │
│       ↓                                         │
│  REDUCED negative feedback → Further ↑LH/FSH    │
│                                                 │
└─────────────────────────────────────────────────┘

Why is FSH often higher than LH?

• LH is regulated by testosterone (partially preserved early)
• FSH is regulated by Inhibin B (profoundly deficient due to Sertoli cell failure)
• Thus, FSH elevation is more pronounced and occurs earlier

Oestrogen Excess:

• Peripheral aromatization of testosterone to oestradiol continues
• Relative oestrogen excess (compared to low testosterone) contributes to:
  • Gynaecomastia
  • Female fat distribution
  • Reduced libido

Clinical Pearl: How to Distinguish Klinefelter from Constitutional Delay of Puberty:

In constitutional delay, the entire HPG axis is immature; in Klinefelter, the axis is active but testes fail to respond.

Why Infertility?

The mechanisms underlying azoospermia in Klinefelter syndrome are multifactorial:

1. Germ cell apoptosis: Extra X chromosome induces germ cell death via unclear mechanisms (possibly disrupted meiotic checkpoints)
2. Impaired spermatogenesis: Sertoli cell dysfunction → loss of germ cell niche
3. Progressive fibrosis: Seminiferous tubule hyalinization obliterates germinal epithelium
4. Low intratesticular testosterone: Despite TRT, intratesticular T levels remain insufficient for spermatogenesis

Can any 47,XXY males produce sperm?

• Yes, rare cases with focal spermatogenesis exist (~40-50% on testicular biopsy) [8]
• Sperm production is transient and deteriorates with age
• This is the basis for TESE-ICSI fertility treatment

---

4. Clinical Presentation

The clinical phenotype of Klinefelter syndrome is highly variable and age-dependent. Many individuals have subtle features and remain undiagnosed throughout life.

Presentation by Age

Neonatal and Infancy

Most infants with Klinefelter syndrome appear phenotypically normal. Occasional features:

• Cryptorchidism (undescended testes): 10-15% (slightly higher than general population)
• Micropenis: Rare, but may occur if testosterone production is severely impaired
• Hypospadias: Uncommon
• Hypotonia: Mild, may delay motor milestones slightly

Most neonatal diagnoses occur incidentally following prenatal genetic testing for advanced maternal age or other indications.

Childhood (2-12 Years)

Neurodevelopmental Features:

• Speech and language delay (50-75%): Expressive language more affected than receptive [18]
• Learning difficulties: Verbal IQ typically 10-15 points lower than performance IQ; mean IQ ~90 (lower end of normal)
• Reading difficulties (dyslexia-like): 50-70%
• Executive function deficits: Planning, organization, attention
• Social difficulties: Immaturity, anxiety, passivity, reduced assertiveness
• Motor coordination delay: Mild dyspraxia or clumsiness

Physical Features:

• Prepubertal testes: May already be smaller than peers (1-2 mL vs. 2-3 mL)
• Height: Often tall for age (> 75th percentile)
• Otherwise unremarkable examination

Key Point: The neurodevelopmental phenotype is variable. Many boys with Klinefelter syndrome have entirely normal cognitive development; others require speech therapy and educational support.

Adolescence (12-18 Years)

This is a critical period for diagnosis, as pubertal features become apparent:

Delayed or Incomplete Puberty:

• Testicular enlargement does not occur (remain less than 4 mL)
• Phallus growth may be reduced
• Pubic/axillary hair develops but is sparse
• Voice deepens incompletely
• Delayed bone age (due to low testosterone)

Tall Stature and Eunuchoid Proportions:

• Height typically > 75th percentile
• Arm span > height by 5-10 cm
• Lower segment > upper segment (long legs relative to trunk)
• Narrow shoulders, wide hips

Gynaecomastia:

• Occurs in 38-75% of adolescents with Klinefelter [6]
• May be unilateral or bilateral
• Often persists into adulthood
• Psychologically distressing; increased risk of social withdrawal

Other Features:

• Sparse facial hair
• Fine, soft skin
• Reduced muscle mass

Exam Detail: Why "Eunuchoid Proportions"?

The term "eunuchoid" refers to skeletal proportions resembling castrated males (eunuchs) who lacked testosterone during puberty:

• Normally, testosterone induces epiphyseal fusion, halting long bone growth
• In hypogonadism (low testosterone), epiphyses remain open longer
• Lower limbs (which grow more during puberty) continue elongating
• Result: Long legs, increased lower segment:upper segment ratio, arm span > height

This is distinct from gigantism (pituitary GH excess), where all segments are proportionately enlarged.

Adulthood (> 18 Years)

Infertility is the most common presentation (60-70% of diagnoses):

• Couples present after 1-2 years of unsuccessful conception attempts
• Semen analysis reveals azoospermia (no sperm) in 90-95%
• Severe oligospermia (very low sperm count) in 5-10% (often mosaic 46,XY/47,XXY)

Hypogonadism Symptoms:

• Reduced libido (low sex drive)
• Erectile dysfunction (ED)
• Reduced energy and fatigue
• Depressed mood, irritability
• Reduced muscle mass and strength
• Increased abdominal adiposity (central obesity)
• Loss of body and facial hair over time

Physical Examination Findings:

Testicular Examination:

• Orchidometer measurement: Testes are less than 4 mL (normal adult: 15-25 mL)
• Consistency: Firm, sometimes described as "hard" due to fibrosis
• Comparison: Normal testis feels like a peeled hard-boiled egg; Klinefelter testis feels firmer

Associated Comorbidities

Adults with Klinefelter syndrome have increased risk of multiple conditions:

Metabolic Disorders

• Metabolic syndrome: 40-50% prevalence [5]
• Type 2 diabetes: 10-40% (OR ~3-4 vs. general population)
• Dyslipidemia: Low HDL, elevated triglycerides
• Obesity: Central adiposity, BMI often elevated

Cardiovascular Disease

• Ischaemic heart disease: Modest increased risk (possibly mediated by metabolic syndrome)
• Venous thromboembolism (VTE): 2-5x increased risk [19]
• Varicose veins and leg ulcers

Bone Health

• Osteoporosis: 25-40% prevalence
• Osteopenia: Even higher prevalence
• Fracture risk: Increased (vertebral and hip fractures)
• Mechanism: Low testosterone → reduced bone mineral density

Autoimmune Disease

• Systemic lupus erythematosus (SLE): 10-15x increased risk
• Rheumatoid arthritis: 2-3x increased risk
• Sjögren's syndrome, autoimmune thyroiditis: Increased prevalence
• Mechanism: Unclear; possibly related to X chromosome gene dosage effects on immune function

Malignancy

• Breast cancer: 20-50x increased risk (lifetime risk ~3%) [11]
• Extragonadal germ cell tumors: Mediastinal GCT (especially in adolescents/young adults)
• Non-Hodgkin lymphoma: Modestly increased risk
• Testicular cancer: REDUCED risk (paradoxical protective effect) [12]

Neuropsychiatric

• Anxiety disorders: 2-3x increased prevalence
• Depression: Increased risk, may improve with TRT
• Autism spectrum disorder: Modestly increased prevalence
• Psychosis/Schizophrenia: Slight increase (especially in 48,XXYY)

Respiratory

• Chronic obstructive pulmonary disease (COPD): Increased risk
• Asthma: Modestly increased prevalence
• Mechanism: Possible immune dysregulation

Dental

• Taurodontism: Enlarged pulp chambers (minor finding)
• Delayed eruption: Slightly delayed dental development

---

5. Clinical Examination

General Inspection

• Body habitus: Tall stature (often > 75th percentile for age), eunuchoid proportions
• Posture: May have narrow shoulders, wider pelvis
• Gait: Usually normal; occasionally mild dyspraxia

Anthropometric Measurements

How to Measure Upper and Lower Segments:

• Lower segment: Pubis to floor (standing height minus sitting height)
• Upper segment: Crown to pubis (sitting height)
• Normal ratio (adult): ~0.95-1.0
• Klinefelter: Often less than 0.9 (relatively long lower segment)

Secondary Sexual Characteristics (Tanner Staging)

Breast Examination

• Gynaecomastia: Palpable in 38-75%
• Inspection: Visible breast enlargement (often bilateral)
• Palpation: Firm subareolar disk of glandular tissue (distinguish from adipose)
• Assess for masses or nipple discharge (breast cancer screening)

Genital Examination

Penis:

• Length: Normal or slightly reduced (stretched penile length typically > 7 cm in adults)
• Circumcision status, hypospadias (rare)

Testes:

• Size: less than 4 mL bilaterally (pathognomonic if post-pubertal)
  • Use Prader orchidometer (ellipsoid beads ranging 1-25 mL)
  • "Normal adult: 15-25 mL; Klinefelter: typically 1-3 mL"
• Consistency: Firm, sometimes hard (due to fibrosis)
• Position: Usually descended; cryptorchidism in 10-15%
• Symmetry: Bilateral small testes (vs. unilateral pathology)

Scrotum and epididymis:

• Usually normal

Clinical Pearl: The Orchidometer: Essential Tool for Klinefelter Diagnosis

The Prader orchidometer is critical for assessing testicular volume:

In an adolescent (> 14 years) or adult with bilateral testicular volumes less than 4 mL, Klinefelter syndrome should be the primary differential diagnosis.

Cardiovascular Examination

• Usually unremarkable
• Assess for signs of metabolic syndrome (central obesity, hypertension)

Musculoskeletal Examination

• Muscle mass: Reduced, especially upper body
• Joint hypermobility: Occasionally present
• Kyphosis: Possible (related to osteoporosis in older adults)

Neurological Examination

• Usually normal
• May have subtle motor coordination difficulties (dyspraxia) in childhood

Examination for Associated Conditions

• Varicose veins (lower limbs)
• Leg ulcers (venous insufficiency)
• Thyroid enlargement (autoimmune thyroiditis)

---

6. Differential Diagnosis

The differential diagnosis depends on the presenting feature:

Delayed/Incomplete Puberty

Azoospermia/Male Infertility

Gynaecomastia

Tall Stature

---

7. Investigations

Diagnostic Investigations

Karyotype Analysis (Gold Standard)

Peripheral blood lymphocyte karyotype is the definitive diagnostic test:

• Technique: G-banding karyotype on stimulated lymphocytes
• Result: 47,XXY in 80-90%; may identify mosaicism (46,XY/47,XXY) or higher aneuploidies
• Sensitivity: > 99% for 47,XXY; may miss low-level mosaicism (less than 10% abnormal cells)

Indications for Karyotype Testing:

• Male infertility (especially azoospermia)
• Delayed or incomplete puberty with small testes
• Tall stature with small testes
• Gynaecomastia with small testes
• Hypergonadotropic hypogonadism (elevated LH/FSH with low testosterone)

Turnaround time: 1-3 weeks

Exam Detail: Why is Karyotype Necessary? Can't Hormones Alone Diagnose Klinefelter?

While the hormonal profile (high LH/FSH, low testosterone) is highly suggestive, karyotype is essential because:

1. Confirms the diagnosis definitively: Hypergonadotropic hypogonadism has other causes (e.g., testicular trauma, chemotherapy, Y chromosome deletions)
2. Identifies mosaicism: 46,XY/47,XXY has better prognosis and fertility potential
3. Detects higher aneuploidies: 48,XXXY or 49,XXXXY require different counseling
4. Informs genetic counseling: Confirms the chromosomal basis and recurrence risk

Thus, every patient with suspected Klinefelter syndrome requires karyotype confirmation.

Hormonal Assessment

Interpretation:

• Hypergonadotropic hypogonadism = High LH/FSH + Low testosterone (primary testicular failure)
• Hypogonadotropic hypogonadism = Low LH/FSH + Low testosterone (pituitary/hypothalamic pathology)

Semen Analysis

Standard semen analysis (WHO 2021 criteria):

• Klinefelter syndrome: Azoospermia (no sperm) in 90-95%
• Mosaic 46,XY/47,XXY: Severe oligospermia (less than 5 million/mL) in 5-10%
• Collection: 2-5 days abstinence, analyze within 1 hour

If sperm present:

• Suggests mosaicism (repeat karyotype with higher cell count or testicular biopsy karyotype)
• May have spontaneous fertility potential (rare)

Genetic Testing

Investigations for Associated Conditions

Bone Health

• DEXA scan (dual-energy X-ray absorptiometry):
  • Indicated in all adults with Klinefelter syndrome
  • Assesses lumbar spine and hip bone mineral density
  • Osteoporosis common (25-40%); osteopenia even more prevalent
  • Repeat every 2-3 years if on TRT

Metabolic Screening

• Fasting glucose and HbA1c: Screen for diabetes (10-40% prevalence)
• Lipid profile: Assess for dyslipidemia (low HDL, high triglycerides)
• BMI and waist circumference: Metabolic syndrome assessment

Cardiovascular

• Blood pressure: Hypertension screening
• ECG: Baseline; some studies suggest QTc prolongation
• Echocardiography: Not routine; consider if cardiac symptoms

Breast Cancer Screening

• Annual breast examination (clinical)
• Mammography: Not routine, but consider if palpable mass or strong family history
• Educate patients on self-examination

Autoimmune Screening (if symptomatic)

• TSH, anti-TPO antibodies: Thyroid autoimmunity
• ANA, anti-dsDNA: SLE (if joint pain, rash, cytopenias)
• Rheumatoid factor, anti-CCP: Rheumatoid arthritis

Fertility Assessment (for couples seeking conception)

---

8. Management

Management of Klinefelter syndrome is multidisciplinary, focusing on testosterone replacement therapy, fertility preservation, comorbidity screening, and psychosocial support. Early diagnosis (ideally in adolescence) enables optimal intervention.

Testosterone Replacement Therapy (TRT)

Testosterone replacement is the cornerstone of treatment, addressing hypogonadism and its sequelae. [7]

Indications for TRT

• Confirmed Klinefelter syndrome (47,XXY) with:
  • Biochemical hypogonadism (low testosterone)
  • AND symptoms (reduced libido, ED, fatigue, reduced muscle mass)
• Initiate during adolescence (typically age 12-14) if testosterone levels fail to rise appropriately during puberty

Goals of TRT

1. Induce/complete puberty (if started in adolescence)
2. Improve sexual function (libido, erectile function)
3. Increase muscle mass and strength
4. Reduce fat mass (especially visceral adiposity)
5. Improve bone mineral density (prevent/treat osteoporosis)
6. Enhance mood and energy
7. Improve quality of life and self-esteem

TRT Formulations

Most Common in UK/Australia: Intramuscular testosterone undecanoate (Nebido) or transdermal gel (Testogel/Tostran)

Initiating TRT in Adolescents

• Start at age 12-14 (when puberty normally begins)
• Begin with low-dose to mimic physiological puberty:
  • "IM: 50 mg testosterone enantate monthly, gradually increasing"
  • "Transdermal gel: 25-50 mg daily, increasing incrementally"
• Gradual escalation over 2-3 years to adult dosing
• Monitor for virilization, growth, bone maturation

Monitoring TRT

Contraindications to TRT

Absolute:

• Prostate cancer
• Male breast cancer
• Uncontrolled heart failure

Relative:

• Severe untreated obstructive sleep apnoea (may worsen)
• Polycythaemia (Hct > 54%)
• Severe lower urinary tract symptoms (LUTS) due to BPH

Side Effects of TRT

Clinical Pearl: "TRT Does NOT Restore Fertility"

Exogenous testosterone suppresses gonadotropins (LH/FSH) via negative feedback, which:

• Further reduces intratesticular testosterone
• Inhibits any residual spermatogenesis

Thus, men on TRT seeking fertility must:

1. Discontinue TRT (at least 3-6 months before TESE attempt)
2. Consider hCG therapy to stimulate intratesticular testosterone
3. Proceed with TESE-ICSI (see below)

For men desiring future fertility, consider deferring TRT or using hCG monotherapy to preserve spermatogenesis.

Fertility Treatment

Natural Fertility in Klinefelter Syndrome

• Azoospermia: 90-95% (no sperm in ejaculate)
• Severe oligospermia: 5-10% (mosaic cases; less than 5 million/mL)
• Spontaneous conception: Rare, but documented in mosaic 46,XY/47,XXY individuals

Testicular Sperm Extraction (TESE) with ICSI

For couples seeking biological parenthood, TESE combined with ICSI is the treatment of choice. [8,9]

Procedure:

1. TESE: Surgical extraction of testicular tissue (micro-TESE preferred)
2. Sperm retrieval: Histological examination for focal spermatogenesis
3. Cryopreservation: Freeze any retrieved sperm
4. ICSI: Inject single sperm directly into oocyte (female partner's egg)
5. Embryo transfer: Standard IVF protocol

Success Rates:

• Sperm retrieval rate: 40-50% (varies by age and centre) [8,9]
• Pregnancy rate per cycle: 30-40% (if sperm retrieved)
• Live birth rate: 25-35% (cumulative over multiple cycles)

Factors Affecting Success:

Timing:

• Optimal age: Late adolescence (16-18 years) or early twenties
• Sperm can be cryopreserved for future use
• Early intervention before progressive testicular fibrosis

Alternatives:

• Donor sperm insemination
• Adoption

Genetic Counseling

Couples undergoing TESE-ICSI require comprehensive genetic counseling:

• Risk of transmitting 47,XXY: Theoretical, but evidence suggests most offspring are chromosomally normal (46,XX or 46,XY)
• Preimplantation genetic testing (PGT): Can screen embryos for aneuploidy before transfer
• Prenatal testing: Amniocentesis or NIPT available during pregnancy

Management of Gynaecomastia

Conservative Management

• Reassurance and education (especially in adolescents)
• TRT may reduce gynaecomastia in some cases (by increasing testosterone:oestrogen ratio)

Medical Management

• Aromatase inhibitors (e.g., anastrozole): May reduce oestrogen; limited evidence in Klinefelter
• Selective oestrogen receptor modulators (e.g., tamoxifen): Rarely used

Surgical Management

• Subcutaneous mastectomy: For persistent, psychologically distressing gynaecomastia
• Best results if performed after breast tissue has matured (> 2 years duration)

Management of Associated Comorbidities

Osteoporosis

• Primary prevention: TRT (most important intervention)
• Calcium and vitamin D supplementation: 1000-1200 mg calcium, 800-1000 IU vitamin D daily
• Bisphosphonates: If DEXA shows osteoporosis despite TRT (T-score ≤-2.5)
• Weight-bearing exercise: Encourage regular physical activity

Metabolic Syndrome and Diabetes

• Lifestyle modification: Diet, exercise, weight loss
• TRT: Improves insulin sensitivity and body composition [7]
• Metformin, statins, antihypertensives: As per standard guidelines

Cardiovascular Risk

• Optimize metabolic risk factors: BP, lipids, glucose, weight
• TRT: May improve cardiovascular risk profile
• Antiplatelet therapy: If indicated by cardiovascular risk score

Venous Thromboembolism (VTE)

• No routine anticoagulation (unless VTE occurs)
• Consider thrombophilia screen if unprovoked VTE
• TRT is NOT contraindicated after VTE (no clear evidence of increased risk)

Breast Cancer Screening

• Annual clinical breast examination
• Patient education on self-examination
• Low threshold for mammography if any palpable abnormality

Psychosocial Support

Educational Support (Childhood/Adolescence)

• Speech and language therapy: For expressive language delay
• Educational psychology: IEP (individualized education plan) if learning difficulties
• Occupational therapy: For motor coordination deficits

Psychological Support

• Counseling: Address body image issues, infertility, social anxiety
• Support groups: Connect with other individuals/families (e.g., KS&A – Klinefelter Syndrome Association)
• Psychiatric referral: If depression, anxiety, or other psychiatric comorbidity

Multidisciplinary Team (MDT)

Optimal care involves:

Monitoring and Long-Term Follow-Up

Lifelong follow-up is required:

---

9. Complications

Complications of the Syndrome

Complications of Treatment (TRT)

---

10. Prognosis and Outcomes

Life Expectancy

• With treatment: Life expectancy approaches normal population [20]
• Without treatment: Modest reduction (possibly 5-10 years) due to metabolic, cardiovascular, and osteoporotic complications
• Main determinants of prognosis: Early diagnosis, TRT adherence, comorbidity management

Quality of Life

Untreated:

• Reduced quality of life scores (physical, psychological, sexual domains)
• Social isolation, body image issues, low self-esteem
• Psychosexual difficulties, relationship strain (infertility)

With TRT:

• Significant improvement in energy, mood, sexual function, muscle mass, and bone density [7]
• Reduction in fat mass, improved metabolic parameters
• Enhanced self-esteem and social functioning

Fertility Outcomes

• Without intervention: > 95% lifetime infertility
• With TESE-ICSI: 40-50% sperm retrieval rate; 25-35% live birth rate (cumulative)
• Best outcomes: Early intervention (adolescence/early twenties), mosaic karyotype

Neurodevelopmental Outcomes

• IQ: Mean ~90 (lower end of normal); most function independently
• Educational attainment: Variable; many complete higher education with support
• Employment: Most are employed; some require workplace accommodations
• Social functioning: Increased risk of social anxiety, but most have meaningful relationships

Comorbidity-Specific Outcomes

Predictors of Favorable Prognosis

---

11. Prevention and Screening

Primary Prevention

Klinefelter syndrome results from sporadic chromosomal non-disjunction and cannot be prevented. Recurrence risk in subsequent pregnancies is not increased (unlike familial genetic conditions).

Secondary Prevention (Early Detection)

Prenatal Screening:

• Non-invasive prenatal testing (NIPT): Detects sex chromosome aneuploidies from cell-free fetal DNA (from 10 weeks gestation)
• Amniocentesis/CVS: Karyotype analysis if NIPT positive or other indications
• Ethical considerations: Counseling regarding variable phenotype; many affected individuals lead fulfilling lives

Postnatal Screening:

• No population-based screening program exists
• High index of suspicion in:
  • Boys with learning difficulties + tall stature
  • Adolescents with delayed puberty + small testes
  • Men with infertility + hypergonadotropic hypogonadism

Newborn Screening:

• Not currently recommended (most newborns are asymptomatic)
• Debate exists regarding benefits of early diagnosis (enabling early intervention) vs. potential psychological harm (labeling, anxiety)

Tertiary Prevention (Complication Prevention)

---

12. Guidelines and Evidence

Key Clinical Guidelines

1. Endocrine Society Clinical Practice Guideline: Testosterone Therapy in Men with Hypogonadism (2018) [7]

   • Recommends TRT for symptomatic hypogonadism in Klinefelter syndrome
   • Target testosterone levels: mid-normal range (15-20 nmol/L)
   • Monitoring: Testosterone, Hct, PSA (if > 40 years), bone density, symptoms

2. European Academy of Andrology (EAA) Guidelines on Klinefelter Syndrome (2020)

   • Comprehensive guidance on diagnosis, TRT, fertility management
   • Recommends early diagnosis and TRT initiation in adolescence
   • Advocates for TESE-ICSI as fertility treatment; optimal timing in late teens/early twenties

3. American Academy of Pediatrics (AAP): Health Supervision for Children with Klinefelter Syndrome (2011)

   • Recommends developmental screening, educational support
   • Endocrine referral at onset of puberty
   • Psychosocial support and family counseling

Landmark Studies

Diagnosis and Epidemiology

• Bojesen A, et al. (2003): Klinefelter syndrome incidence 1 in 660; only 25% diagnosed [3]
• Abramsky L, Chapple J (1997): Prenatal diagnosis and outcomes of sex chromosome aneuploidies [15]

Testosterone Replacement Therapy

• Aksglaede L, et al. (2013): TRT improves bone mineral density, body composition, and quality of life in Klinefelter syndrome [7]
• Zitzmann M, et al. (2015): Long-term TRT in Klinefelter syndrome: benefits on metabolic parameters and cardiovascular risk [7]

Fertility

• Ramasamy R, et al. (2009): Successful sperm retrieval in adolescent males with Klinefelter syndrome via micro-TESE [9]
• Plotton I, et al. (2015): TESE-ICSI outcomes in Klinefelter syndrome; sperm retrieval rate 40-50%; live birth rate 25-30% [8]

Comorbidities

• Swerdlow AJ, et al. (2005): Breast cancer risk in Klinefelter syndrome: 20-50x increased risk [11]
• Bojesen A, et al. (2006): Morbidity and mortality in Klinefelter syndrome: increased risk of metabolic, cardiovascular, and autoimmune disease [20]

Neurodevelopment

• Leggett V, et al. (2010): Language and literacy deficits in boys with Klinefelter syndrome [18]
• Van Rijn S, et al. (2014): Social cognition and autism spectrum features in Klinefelter syndrome [18]

---

13. Examination Focus

MRCP/FRACP PACES Clinical Examination

Station: Endocrine or abdominal examination (male patient with infertility or hypogonadism)

Likely Scenario:

"This 28-year-old man has been referred by his GP for investigation of infertility. Please examine him and discuss your findings."

Key Examination Findings:

1. General inspection: Tall stature (> 75th percentile), eunuchoid proportions (arm span > height)
2. Secondary sexual characteristics: Sparse facial/body/axillary hair, incomplete virilization
3. Gynaecomastia: Bilateral palpable breast tissue
4. Genital examination: Small, firm testes (less than 4 mL bilaterally, using orchidometer); normal phallus
5. Body composition: Reduced muscle mass, increased truncal adiposity

Presentation:

"This tall gentleman has features of hypogonadism. On examination, he has sparse body hair, bilateral gynaecomastia, and most significantly, bilaterally small, firm testes measuring approximately 2 mL each. His arm span exceeds his height, consistent with eunuchoid proportions. These findings suggest Klinefelter syndrome (47,XXY). I would confirm this with karyotype analysis and assess the hormonal profile, expecting hypergonadotropic hypogonadism (elevated LH and FSH with low testosterone)."

Examiner Questions:

Q1: What is the karyotype in Klinefelter syndrome?

"The most common karyotype is 47,XXY, accounting for 80-90% of cases. There is one extra X chromosome. Mosaicism (46,XY/47,XXY) occurs in 10-20% and typically has a milder phenotype. Rarer variants include 48,XXXY and 49,XXXXY with progressively severe features."

Q2: What is the hormonal profile?

"Klinefelter syndrome causes primary hypergonadotropic hypogonadism. The dysgenic testes fail to produce adequate testosterone, so the pituitary increases LH and FSH in a compensatory response. Typically, testosterone is low-normal to low (5-12 nmol/L), LH is elevated (10-30 IU/L), and FSH is markedly elevated (15-50 IU/L). Inhibin B is low or undetectable, reflecting Sertoli cell failure."

Q3: Why is this man infertile?

"Infertility results from azoospermia (absent sperm in ejaculate), seen in 90-95% of men with Klinefelter syndrome. The supernumerary X chromosome causes progressive germ cell apoptosis and seminiferous tubule fibrosis. By adulthood, testicular histology shows hyalinized tubules with absent spermatogenesis. Rarely, focal areas of spermatogenesis persist, allowing sperm retrieval via TESE (testicular sperm extraction) for use in ICSI (intracytoplasmic sperm injection)."

Q4: How would you manage this patient?

"Management is multidisciplinary:

1. Confirm diagnosis: Karyotype analysis
2. Testosterone replacement therapy (TRT): To improve sexual function, bone density, muscle mass, energy, and quality of life. Options include IM testosterone undecanoate (Nebido) every 10-12 weeks or daily transdermal gel.
3. Fertility counseling: Discuss TESE-ICSI (sperm retrieval rate 40-50%, live birth rate 25-35%) vs. donor sperm or adoption.
4. Screen for complications: DEXA scan for osteoporosis, fasting glucose/lipids for metabolic syndrome, annual breast examination (20x increased breast cancer risk).
5. Long-term monitoring: Annual testosterone levels, FBC (for polycythaemia), metabolic parameters, and psychosocial support as needed."

Q5: What is the breast cancer risk in Klinefelter syndrome?

"Men with Klinefelter syndrome have a 20-50 fold increased risk of breast cancer compared to 46,XY males, although the absolute lifetime risk remains relatively low (~3%). The mechanism is thought to involve relative oestrogen excess (from peripheral aromatization) and genetic factors. Annual clinical breast examination is recommended, with a low threshold for mammography if any palpable abnormality is detected."

Q6: What is the testicular cancer risk?

"Paradoxically, men with Klinefelter syndrome have a reduced risk of testicular cancer compared to the general male population, unlike other disorders of sex development (e.g., androgen insensitivity syndrome, gonadal dysgenesis) which carry increased risk. However, they do have an increased risk of extragonadal germ cell tumors, particularly in the mediastinum, presenting in adolescence or young adulthood."

Viva Voce Scenarios

Viva Question 1: Differential Diagnosis of Azoospermia

Examiner: "A 30-year-old man presents with 2 years of infertility. Semen analysis shows azoospermia. How would you investigate this?"

Model Answer:

"I would take a comprehensive history and examination, then categorize azoospermia as obstructive vs. non-obstructive:

History:

• Previous inguinal/scrotal surgery, infections (epididymitis), chemotherapy, radiation
• Sexual function, libido (hypogonadism?)
• Developmental history (delayed puberty?)
• Family history (cystic fibrosis, infertility)

Examination:

• Testicular volume (orchidometer): less than 4 mL suggests Klinefelter or primary testicular failure; normal (15-25 mL) suggests obstructive cause
• Vas deferens palpation: Absent suggests CBAVD (congenital bilateral absence of vas deferens; cystic fibrosis)
• Varicocele: Palpable on standing; may impair spermatogenesis
• Secondary sexual characteristics: Gynaecomastia, sparse hair (hypogonadism?)

Investigations:

1. Hormonal profile: LH, FSH, testosterone
   • Hypergonadotropic (high LH/FSH): Primary testicular failure (Klinefelter, Y deletions, chemotherapy)
   • Hypogonadotropic (low LH/FSH): Pituitary/hypothalamic (Kallmann, hypopituitarism)
   • Normal hormones: Suggests obstructive azoospermia
2. Karyotype: If small testes or elevated FSH (Klinefelter syndrome)
3. Y chromosome microdeletion analysis: If elevated FSH with normal-sized testes
4. CFTR gene testing: If vas deferens absent or low ejaculate volume (CBAVD)
5. Scrotal ultrasound: Assess testicular parenchyma, epididymal cysts (obstruction)
6. Testicular biopsy: Distinguishes obstructive (normal spermatogenesis) from non-obstructive (Sertoli-cell-only, maturation arrest)

If small testes + elevated LH/FSH, Klinefelter syndrome is the most likely diagnosis; confirm with karyotype."

Viva Question 2: Managing an Adolescent with Newly Diagnosed Klinefelter Syndrome

Examiner: "A 14-year-old boy is diagnosed with Klinefelter syndrome after karyotype testing for delayed puberty. How would you counsel the family and manage him?"

Model Answer:

Counseling:

• Explain Klinefelter syndrome: Extra X chromosome (47,XXY), occurring in 1 in 500-660 boys
• Prognosis: With treatment, most lead normal, fulfilling lives with good quality of life
• Features: May have tall stature, delayed puberty, learning difficulties (language-based), potential infertility
• Treatment available: Testosterone replacement will help puberty, muscle/bone development, energy, and mood
• Fertility: Options exist (sperm extraction + IVF) if desired in future

Management Plan:

1. Testosterone Replacement Therapy:
   • Start low-dose TRT now to induce puberty (e.g., IM testosterone 50 mg monthly, or transdermal gel 25 mg daily)
   • Gradually increase over 2-3 years to adult dosing
   • Monitor for virilization, growth, bone maturation
2. Fertility Counseling:
   • Discuss option of testicular sperm extraction (TESE) in late teens (16-18 years) or early twenties
   • Sperm can be cryopreserved for future use with IVF/ICSI
   • Success rate: 40-50% sperm retrieval; 25-35% live birth rate
   • Emphasize earlier is better (before progressive testicular fibrosis)
3. Educational/Psychological Support:
   • Liaise with school: May need speech/language therapy, educational psychology input
   • Assess for learning difficulties, provide accommodations (e.g., extra time for exams)
   • Consider psychology referral for body image, self-esteem support
4. Baseline Investigations:
   • Hormonal profile (LH, FSH, testosterone)
   • DEXA scan (baseline bone density)
   • Fasting glucose, lipids (metabolic screening)
5. Long-term Follow-up:
   • Annual endocrine review: Testosterone levels, growth, pubertal development
   • Transition to adult endocrinology at age 16-18
   • Annual screening for comorbidities (metabolic syndrome, osteoporosis, breast cancer in adulthood)
6. Multidisciplinary Team:
   • Paediatric endocrinology, urology (fertility), genetics, psychology, school support

Key Message to Family: 'With early testosterone treatment and appropriate support, your son can expect a healthy, fulfilling life. Fertility options are available if desired in the future.'"

---

14. Patient/Layperson Explanation

What is Klinefelter Syndrome?

Klinefelter syndrome is a genetic condition affecting males. It occurs when a boy is born with an extra X chromosome in his cells. Normally, males have one X and one Y chromosome (XY), but in Klinefelter syndrome, there is an extra X, making it XXY (47,XXY).

This extra chromosome affects the development of the testicles (testes), leading to lower levels of the male hormone testosterone.

How Common is It?

Klinefelter syndrome affects about 1 in 500-660 boys born. It is the most common chromosomal condition affecting males. However, many people with Klinefelter syndrome are never diagnosed because the features can be mild.

What Are the Signs and Symptoms?

The features of Klinefelter syndrome vary widely. Some people have very few symptoms, while others are more affected.

In Childhood:

• Some boys may have speech or learning difficulties, especially with reading and language
• May be shy, less assertive, or have social challenges
• Motor skills (coordination) may be slightly delayed

In Adolescence (Teenage Years):

• Taller than average height
• Delayed or incomplete puberty: Testicles remain small, less facial and body hair
• Breast tissue development (gynaecomastia) – can be distressing
• Long arms and legs relative to the body

In Adulthood:

• Infertility (difficulty having children) – this is the most common reason adults discover they have Klinefelter syndrome
• Small, firm testicles (smaller than a grape)
• Reduced body and facial hair
• Low sex drive or erectile problems
• Tiredness and low energy
• Increased risk of weak bones (osteoporosis), diabetes, and breast cancer (although still rare in men)

How is it Diagnosed?

Klinefelter syndrome is diagnosed with a blood test called a karyotype, which looks at the chromosomes in your cells. It confirms the presence of the extra X chromosome (47,XXY).

Blood tests also measure hormone levels:

• Testosterone (male hormone): Lower than normal
• LH and FSH (hormones from the brain that control the testicles): Higher than normal

What is the Treatment?

Although Klinefelter syndrome cannot be "cured" (the extra chromosome is in every cell), treatment can greatly improve quality of life:

1. Testosterone Replacement Therapy (TRT)

Most males with Klinefelter syndrome benefit from testosterone treatment, usually started during teenage years.

How is it given?

• Injections (every few weeks or months)
• Daily gel applied to the skin
• Patches or tablets

What does it do?

• Helps puberty progress normally (deeper voice, facial hair, muscle development)
• Improves energy, mood, and sex drive
• Increases muscle and bone strength
• Improves quality of life

Important: Testosterone therapy does NOT restore fertility (ability to have children).

2. Fertility Treatment

Many men with Klinefelter syndrome want to have children. Although most have no sperm in their semen (azoospermia), fertility is sometimes possible through:

• Testicular sperm extraction (TESE): A small surgical procedure to retrieve sperm directly from the testicles
• ICSI (Intracytoplasmic Sperm Injection): A type of IVF where a single sperm is injected into an egg

Success rate: About 40-50% of men have sperm that can be retrieved, and 25-35% of couples achieve a pregnancy.

Best results occur when the procedure is done in late teens or early twenties, before the testicles become too scarred.

3. Managing Breast Tissue (Gynaecomastia)

If breast tissue is large or causing distress, surgery (mastectomy) can be performed to remove it.

4. Support for Learning and Psychological Wellbeing

• Speech and language therapy for younger children
• Educational support at school (extra help with reading, writing, organization)
• Counseling or psychology support for self-esteem, body image, or anxiety

What About Long-Term Health?

People with Klinefelter syndrome may have a slightly increased risk of certain health conditions, so regular check-ups are important:

• Weak bones (osteoporosis): Bone density scans (DEXA) are done to check bone strength. Calcium, vitamin D, and testosterone treatment help keep bones strong.
• Diabetes and heart disease: Blood sugar and cholesterol are monitored regularly. Healthy lifestyle (diet, exercise, not smoking) is important.
• Breast cancer: Although rare, men with Klinefelter syndrome have a higher risk than other men. Self-examination and annual doctor checks are recommended.

Can People with Klinefelter Syndrome Live a Normal Life?

Yes, absolutely. With testosterone treatment and appropriate support, most people with Klinefelter syndrome live healthy, fulfilling lives. Many complete higher education, have successful careers, and form meaningful relationships.

The key is early diagnosis and treatment – starting testosterone therapy during teenage years leads to the best outcomes.

Where Can I Get Support?

• Klinefelter Syndrome Association (KS&A): Support groups, information, and connection with others (UK, Australia, USA)
• Genetic counseling: Helps families understand the condition and inheritance
• Endocrinologist: Specialist doctor who manages hormone treatment

---

15. References

Primary Guidelines and Reviews

1. Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E. Klinefelter's syndrome. Lancet. 2004;364(9430):273-283. doi:10.1016/S0140-6736(04)16678-6 [PMID: 15262102]

2. Groth KA, Skakkebæk A, Høst C, Gravholt CH, Bojesen A. Klinefelter syndrome – a clinical update. J Clin Endocrinol Metab. 2013;98(1):20-30. doi:10.1210/jc.2012-2382 [PMID: 23118419]

3. Bojesen A, Juul S, Gravholt CH. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J Clin Endocrinol Metab. 2003;88(2):622-626. doi:10.1210/jc.2002-021491 [PMID: 12574191]

4. Aksglaede L, Juul A. Testicular function and fertility in men with Klinefelter syndrome: a review. Eur J Endocrinol. 2013;168(4):R67-R76. doi:10.1530/EJE-12-0934 [PMID: 23504510]

5. Bojesen A, Kristensen K, Birkebaek NH, et al. The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care. 2006;29(7):1591-1598. doi:10.2337/dc06-0145 [PMID: 16801584]

6. Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011;96(8):2430-2439. doi:10.1210/jc.2010-3012 [PMID: 21697255]

7. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. doi:10.1210/jc.2018-00229 [PMID: 29562364]

8. Plotton I, Giscard d'Estaing S, Cuzin B, et al. Preliminary results of a prospective study of testicular sperm extraction in young versus adult patients with nonmosaic 47,XXY Klinefelter syndrome. J Clin Endocrinol Metab. 2015;100(3):961-967. doi:10.1210/jc.2014-3083 [PMID: 25494661]

9. Ramasamy R, Ricci JA, Palermo GD, Gosden LV, Rosenwaks Z, Schlegel PN. Successful fertility treatment for Klinefelter's syndrome. J Urol. 2009;182(3):1108-1113. doi:10.1016/j.juro.2009.05.019 [PMID: 19616804]

10. Thomas NS, Hassold TJ. Aberrant recombination and the origin of Klinefelter syndrome. Hum Reprod Update. 2003;9(4):309-317. doi:10.1093/humupd/dmg028 [PMID: 12926526]

11. Swerdlow AJ, Schoemaker MJ, Higgins CD, Wright AF, Jacobs PA. Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Natl Cancer Inst. 2005;97(16):1204-1210. doi:10.1093/jnci/dji240 [PMID: 16106024]

12. Hasle H, Mellemgaard A, Nielsen J, Hansen J. Cancer incidence in men with Klinefelter syndrome. Br J Cancer. 1995;71(2):416-420. doi:10.1038/bjc.1995.85 [PMID: 7841064]

13. Aksglaede L, Skakkebaek NE, Almstrup K, Juul A. Clinical and biological parameters in 166 boys, adolescents and adults with nonmosaic Klinefelter syndrome: a Copenhagen experience. Acta Paediatr. 2011;100(6):793-806. doi:10.1111/j.1651-2227.2011.02246.x [PMID: 21342256]

14. Ferlin A, Raicu F, Gatta V, Zuccarello D, Palka G, Foresta C. Male infertility: role of genetic background. Reprod Biomed Online. 2007;14(6):734-745. doi:10.1016/s1472-6483(10)60677-3 [PMID: 17579989]

15. Abramsky L, Chapple J. 47,XXY (Klinefelter syndrome) and 47,XYY: estimated rates of and indication for postnatal diagnosis with implications for prenatal counselling. Prenat Diagn. 1997;17(4):363-368. [PMID: 9160389]

16. Tartaglia N, Ayari N, Howell S, D'Epagnier C, Zeitler P. 48,XXYY, 48,XXXY and 49,XXXXY syndromes: not just variants of Klinefelter syndrome. Acta Paediatr. 2011;100(6):851-860. doi:10.1111/j.1651-2227.2011.02235.x [PMID: 21342258]

17. Vawter MP, Harvey PD, DeLisi LE. Dysregulation of X-linked gene expression in Klinefelter's syndrome and association with verbal cognition. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(6):728-734. doi:10.1002/ajmg.b.30454 [PMID: 17347995]

18. Leggett V, Jacobs P, Nation K, Scerif G, Bishop DVM. Neurocognitive outcomes of individuals with a sex chromosome trisomy: XXX, XYY, or XXY: a systematic review. Dev Med Child Neurol. 2010;52(2):119-129. doi:10.1111/j.1469-8749.2009.03545.x [PMID: 20059514]

19. Campbell WA, Price WH. Venous thromboembolic disease in Klinefelter's syndrome. Clin Genet. 1981;19(4):275-280. doi:10.1111/j.1399-0004.1981.tb00711.x [PMID: 7296941]

20. Bojesen A, Juul S, Birkebaek N, Gravholt CH. Increased mortality in Klinefelter syndrome. J Clin Endocrinol Metab. 2004;89(8):3830-3834. doi:10.1210/jc.2004-0777 [PMID: 15292313]

---